Effectiveness of the Diaphragm for HIV Prevention

• ClinicalTrials.gov Identifier: NCT00121459
• Recruitment Status: Withdrawn
• First Posted: July 21, 2005
• Last Update Posted: March 4, 2015
• Sponsor: University of California, San Francisco
• Collaborators: Bill and Melinda Gates Foundation; Ibis Reproductive Health; Medical Research Council, South Africa; Women's Health Global Imperative; UZ-UCSF Collaborative Research Programme; Perinatal HIV Research Unit of the University of the Witswatersrand
• Information provided by: University of California, San Francisco

Tracking Information

• First Submitted Date: July 12, 2005
• First Posted Date: July 21, 2005
• Last Update Posted Date: March 4, 2015
• Study Start Date: September 2003
• Primary Completion Date: Not Provided
• Current Primary Outcome Measures (submitted: July 19, 2005): HIV incidence
• Original Primary Outcome Measures: Same as current

Current Secondary Outcome Measures (submitted: July 19, 2005)

• STI incidence (CT, NG, syphilis, trichomoniasis, HSV2)
• acceptability
• feasibility and sustainability

• Original Secondary Outcome Measures: Same as current
• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Effectiveness of the Diaphragm for HIV Prevention
• Official Title: The Latex Diaphragm to Prevent HIV Acquisition Among Women: A Female-Controlled, Physical Barrier of the Cervix
• Brief Summary: The purpose of this trial is to determine whether using the diaphragm and a lubricant get can reduce women's risk of acquiring an HIV infection.
• Detailed Description: This multi-site randomized, controlled trial will measure the effectiveness of the diaphragm in preventing heterosexual acquisition of HIV infection among women. This Phase III study is powered to detect effectiveness (biological efficacy combined with adherence) of 33 percent. Women in South Africa and Zimbabwe (N=4,500) at risk of contracting HIV will be invited to participate and will be followed for up to 24 months, with a total study duration of 4 years. All women will receive safer-sex counseling, free male condoms and diagnosis and treatment of sexually transmitted infections (STIs). Half of the participants will be randomly selected to receive an Ortho All-Flex latex diaphragm and Replens lubricant gel. We will assess whether women using diaphragms and lubricant gel have lower rates of HIV or STI infection than do their non-diaphragm and gel counterparts. Additionally, we will investigate the long-term acceptability of the diaphragm in this study population.
• Study Type: Interventional
• Study Phase: Phase 3
• Study Design: Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: None (Open Label); Primary Purpose: Prevention
• Condition: HIV Infection
• Intervention: Device: Ortho All-Flex diaphragm and Replens lubricant gel
• Study Arms: Not Provided

Publications *

• Teasdale CA, Abrams EJ, Chiasson MA, Justman J, Blanchard K, Jones HE. Incidence of sexually transmitted infections during pregnancy. PLoS One. 2018 May 24;13(5):e0197696. doi: 10.1371/journal.pone.0197696. eCollection 2018.
• Abbai NS, Wand H, Ramjee G. Biological factors that place women at risk for HIV: evidence from a large-scale clinical trial in Durban. BMC Womens Health. 2016 Mar 19;16:19. doi: 10.1186/s12905-016-0295-5.
• Abbai NS, Wand H, Ramjee G. Socio-demographic and behavioural characteristics associated with HSV-2 sero-prevalence in high risk women in KwaZulu-Natal. BMC Res Notes. 2015 May 5;8:185. doi: 10.1186/s13104-015-1093-0.
• Naidoo S, Wand H, Abbai NS, Ramjee G. High prevalence and incidence of sexually transmitted infections among women living in Kwazulu-Natal, South Africa. AIDS Res Ther. 2014 Sep 15;11:31. doi: 10.1186/1742-6405-11-31. eCollection 2014.
• Ramjee G, Wand H. Geographical clustering of high risk sexual behaviors in "hot-spots" for HIV and sexually transmitted infections in Kwazulu-Natal, South Africa. AIDS Behav. 2014 Feb;18(2):317-22. doi: 10.1007/s10461-013-0578-x.
• Wand H, Ramjee G. The relationship between age of coital debut and HIV seroprevalence among women in Durban, South Africa: a cohort study. BMJ Open. 2012 Jan 5;2(1):e000285. doi: 10.1136/bmjopen-2011-000285. Print 2012. Erratum In: BMJ Open. 2012 Sep 10;2(5):null.
• Blanchard K, Bostrom A, Montgomery E, van der Straten A, Lince N, de Bruyn G, Grossman D, Chipato T, Ramjee G, Padian N. Contraception use and effectiveness among women in a trial of the diaphragm for HIV prevention. Contraception. 2011 Jun;83(6):556-63. doi: 10.1016/j.contraception.2010.10.018. Epub 2011 Jan 26.
• de Bruyn G, Shiboski S, van der Straten A, Blanchard K, Chipato T, Ramjee G, Montgomery E, Padian N; MIRA Team. The effect of the vaginal diaphragm and lubricant gel on acquisition of HSV-2. Sex Transm Infect. 2011 Jun;87(4):301-5. doi: 10.1136/sti.2010.047142. Epub 2011 Mar 29.
• van der Straten A, Cheng H, Minnis AM. Change in condom and other barrier method use during and after an HIV prevention trial in Zimbabwe. J Int AIDS Soc. 2010 Oct 19;13:39. doi: 10.1186/1758-2652-13-39.
• Sawaya GF, Chirenje MZ, Magure MT, Tuveson JL, Ma Y, Shiboski SC, Da Costa MM, Palefsky JM, Moscicki AB, Mutasa RM, Chipato T, Smith-McCune KK. Effect of diaphragm and lubricant gel provision on human papillomavirus infection among women provided with condoms: a randomized controlled trial. Obstet Gynecol. 2008 Nov;112(5):990-7. doi: 10.1097/AOG.0b013e318189a8a4. Erratum In: Obstet Gynecol. 2010 Sep;116(3):775. Obstet Gynecol. 2016 Aug;128(2):411.
• Ramjee G, van der Straten A, Chipato T, de Bruyn G, Blanchard K, Shiboski S, Cheng H, Montgomery E, Padian N; MIRA team. The diaphragm and lubricant gel for prevention of cervical sexually transmitted infections: results of a randomized controlled trial. PLoS One. 2008;3(10):e3488. doi: 10.1371/journal.pone.0003488. Epub 2008 Oct 22.
• Padian NS, van der Straten A, Ramjee G, Chipato T, de Bruyn G, Blanchard K, Shiboski S, Montgomery ET, Fancher H, Cheng H, Rosenblum M, van der Laan M, Jewell N, McIntyre J; MIRA Team. Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: a randomised controlled trial. Lancet. 2007 Jul 21;370(9583):251-261. doi: 10.1016/S0140-6736(07)60950-7.

Recruitment Information

• Recruitment Status: Withdrawn
• Actual Enrollment (submitted: March 3, 2015): 0
• Original Enrollment (submitted: July 19, 2005): 5000
• Study Completion Date: Not Provided
• Primary Completion Date: Not Provided

Eligibility Criteria

Inclusion Criteria:

• Age 18 to 49 years old
• Sexually active (coital frequency at least four times per month on average)
• HIV negative based on testing within two weeks prior to enrollment
• Chlamydia trachomatis and Neisseria gonorrhoeae negative based on testing within 30 days prior to enrollment or if positive, completes treatment before enrollment
• Have a healthy cervix, as assessed by naked-eye speculum exam at enrollment
• Planning to live in the study area for the next 24 months
• Willing to be randomly assigned either to use or not use a latex diaphragm with lubricant gel during participation in the study, and to follow the protocol, including being tested for HIV and STIs
• Willing and able to give informed consent

Exclusion Criteria:

• Known sensitivity or allergy to latex
• History of TSS (as suggested by current labeling for diaphragm use)
• Currently pregnant, or desiring to become pregnant in the next two years
• No cervix (total hysterectomy)
• Refuses treatment for diagnosed or suspected current STI and/or reproductive tract infection requiring treatment at enrollment
• Within six weeks of any pelvic surgery or last pregnancy outcome at the time of screening and enrollment
• Presence of clinically apparent lesion(s) with epithelial disruption at enrollment (may enroll after lesion(s) has healed, if otherwise eligible)
• Injected illicit drugs in the 12 months prior to screening and enrollment
• Blood transfusion or received blood products in 3 months prior to screening and enrollment
• Unable or unwilling to insert the diaphragm correctly
• Participation in any other clinical trial (including those of a vaginal product or barrier contraceptive). Verification by comparing participant lists to other concurrently running research studies may be conducted if necessary.
• Unable to speak English, Zulu, Shona, or Sotho
• Other conditions that, in the opinion of the investigator, would constitute contraindications to participation in the study or would compromise ability to comply with the study protocol, such as a major psychiatric disorder

Sex/Gender

• Sexes Eligible for Study: Female

• Ages: 18 Years to 49 Years (Adult)
• Accepts Healthy Volunteers: Yes
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: South Africa, Zimbabwe

Administrative Information

• NCT Number: NCT00121459
• Other Study ID Numbers: H6070-22217-03; 21082
• Has Data Monitoring Committee: Not Provided
• U.S. FDA-regulated Product: Not Provided
• IPD Sharing Statement: Not Provided
• Current Responsible Party: Not Provided
• Original Responsible Party: Same as current
• Current Study Sponsor: University of California, San Francisco
• Original Study Sponsor: Same as current

Collaborators

• Bill and Melinda Gates Foundation
• Ibis Reproductive Health
• Medical Research Council, South Africa
• Women's Health Global Imperative
• UZ-UCSF Collaborative Research Programme
• Perinatal HIV Research Unit of the University of the Witswatersrand

Investigators

• Principal Investigator: Nancy Padian, PhD; University of California, San Francisco

• PRS Account: University of California, San Francisco
• Verification Date: March 2015